# Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors

> **NCT06563375** · PHASE1 · RECRUITING · sponsor: **M.D. Anderson Cancer Center** · enrollment: 35 (estimated)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** NP-101

## Key facts

- **NCT ID:** NCT06563375
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-03-05
- **Primary completion:** 2028-09-01
- **Final completion:** 2030-09-01
- **Target enrollment:** 35 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06563375

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06563375, "Phase 1 Dose Escalation and Dose Expansion Trial of NP-101 in Patients With Solid Tumors". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06563375. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*